Okładka

Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries

Lung cancer is a devastating disease with a high incidence, mortality and morbidity rate, especially in developing countries. Conventional treatment with cytotoxic chemotherapy has some limitations attributed to chemoresistance and toxicity. Recent advances have shown that first generation Tyrosine...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
Główni autorzy:	Zulkifli Amin (Autor), Vito Filbert Jayalie (Autor), Wulyo Rajabto (Autor)
Format:	Książka
Wydane:	Interna Publishing, 2017-04-01T00:00:00Z.
Hasła przedmiotowe:	article
Dostęp online:	Connect to this object online.
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
od: Naoyuki Nishiya, i wsp.
Wydane: (2019)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
od: Connor O'Leary, i wsp.
Wydane: (2020)

Epidermal growth factor receptor mutations in adenocarcinoma lung: Comparison of techniques for mutation detection
od: Saumya Shukla, i wsp.
Wydane: (2022)

Evaluation of Epidermal Growth Factor Receptor Gene Mutations in an Iranian Population with Non-Small Cell Lung Carcinoma
od: Hamzeh Salmani, i wsp.
Wydane: (2022)

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
od: Giuliano Palumbo, i wsp.
Wydane: (2020)

Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
od: Sang Hwa Lee, i wsp.
Wydane: (2015)

Mucin Production Correlates with Dual Expression of Epidermal Growth Factor Receptor and Its Ligand the Epidermal Growth Factor in Non-Small Cell Lung Cancer
od: Rancés Blanco, i wsp.
Wydane: (2017)

Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes
od: Xin Yin, i wsp.
Wydane: (2022)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
od: Ping-Chih Hsu, i wsp.
Wydane: (2020)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
od: Haifeng Qin, i wsp.
Wydane: (2021)

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach
od: Francesca Di Pressa, i wsp.
Wydane: (2024)

Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18-21 mutations
od: Nikolova Dafina, i wsp.
Wydane: (2022)

Leser-Trelat sign: Eruptive seborrheic keratoses and primary lung adenocarcinomas with an epidermal growth factor receptor mutation
od: August Mathien, BS, i wsp.
Wydane: (2023)

Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns
od: Pankaj Gupta, i wsp.
Wydane: (2019)

Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report from Iran
od: Sahand Mohammadzadeh, i wsp.
Wydane: (2019)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
od: Vavalà T
Wydane: (2017)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
od: Chih-Jen Yang, i wsp.
Wydane: (2017)

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma
od: Chan Shen, i wsp.
Wydane: (2022)

The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor
od: Kim SH, i wsp.
Wydane: (2016)

The Cardenolide Glycoside Acovenoside A Interferes with Epidermal Growth Factor Receptor Trafficking in Non-Small Cell Lung Cancer Cells
od: Susanne Hafner, i wsp.
Wydane: (2021)

Prognostic role of epidermal growth factor receptors' expression in patients with i-ii stage of non-small cell lung cancer
od: A.P. Kolesnik, i wsp.
Wydane: (2013)

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
od: Pignata M, i wsp.
Wydane: (2017)

Impact of Dose Reduction of Afatinib Used in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
od: Ziyu Wang, i wsp.
Wydane: (2021)

Biodegradable Carbonate Apatite Nanoparticle as a Delivery System to Promote Afatinib Delivery for Non-Small Cell Lung Cancer Treatment
od: Nian N. N. Maarof, i wsp.
Wydane: (2022)

The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer
od: Ashwaq Al Olayan, i wsp.
Wydane: (2012)

Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
od: Xueke Zhou, i wsp.
Wydane: (2010)

Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
od: Xueke Zhou, i wsp.
Wydane: (2010)

Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients
od: Xiao Liu, i wsp.
Wydane: (2021)

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
od: Simon Ekman, i wsp.
Wydane: (2023)

First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
od: Chongxiang Chen, i wsp.
Wydane: (2022)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
od: Isla D, i wsp.
Wydane: (2016)

Oestrogen receptor β5 and epidermal growth factor receptor synergistically promote lung cancer progression
od: Yuquan Bai, i wsp.
Wydane: (2018)

Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations
od: Lv Ning, i wsp.
Wydane: (2011)

How to Diagnose, Treat, and Monitor Treatment Response in Patients with Multiple Myeloma
od: Wulyo Rajabto, i wsp.
Wydane: (2022)

Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?
od: Wulyo Rajabto, i wsp.
Wydane: (2022)

Anticancer Evaluation of Novel Benzofuran-Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells
od: Yechan Lee, i wsp.
Wydane: (2024)

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
od: Varella-Garcia Marileila
Wydane: (2006)

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry studyResearch in context
od: Rolof G.P. Gijtenbeek, i wsp.
Wydane: (2023)

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
od: Sviatoslav Chekhun, i wsp.
Wydane: (2023)

Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
od: Xu Y, i wsp.
Wydane: (2016)